This promotional webinar has been initiated and commissioned by Boehringer Ingelheim Limited and organised in partnership with Guidelines in Practice. Boehringer Ingelheim Limited has reviewed the scope of the webinar, commissioned the speaker, and approved all materials related to the webinar. The speaker has been paid an honorarium. The views and opinions of the speaker are not necessarily those of Boehringer Ingelheim Limited, or of Guidelines in Practice, its publisher, advisers, or advertisers.

Boehringer Ing 288 logo_RGB

View prescribing information

The webinar is intended for UK healthcare professionals.

Receive your CPD certificate by completing the feedback form here

If you do not wish to complete the feedback form, please email events@mgp.co.uk to request your certificate

 

This 1-hour Guidelines in Practice webinar reviews:

  • the role of breathlessness in the patient experience of COPD
  • the impact of breathlessness on patients’ quality of life
  • the role of pharmacological and non-pharmacological interventions in managing breathlessness in COPD
  • current guidance from NICE and GOLD
  • practical advice on selecting the most appropriate treatment for a patient
  • steps to reduce the environmental impact of inhalers.

 

Feedback from live webinar attendees:

‘Very useful information that will enable me to improve my clinical practice in the community.’

‘Fantastic presentation, very informative.’

‘Very comprehensive and informative presentation. Easy to follow from application to knowledge and skills. Reinforced my confidence. Thank you.’

‘Good slides, good pace, well organised order of delivery.’

‘Very clear and succinct presentation with easily identified take home messages.’

 

James Calvert

Dr James Calvert 
Consultant Respiratory Physician, North Bristol Lung Centre; 
Associate Medical Director, North Bristol NHS Trust

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).

PC-GB-102926

Date of preparation: December 2020